It efficiently suppressed the proliferation of both imatinib-sensitive and -resistant CML cells via the mechanistic target of rapamycin (mTOR)-Unc-51-like kinase 1 (Ulk1) pathway[98] and can sensitize esophageal squamous cell carcinoma to radiotherapy[100]. This evidence concerns the gene ULK1 and chronic myelogenous leukemia, BCR-ABL1 positive.